Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers

Pharmacology and Therapeutics

Volumn 128, Issue 3, 2010, Pages 509-518

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AMD300, Plerixafor, ozobil ; CD34+ cells; CXCR4; Granulocyte colony stimulating factor (G CSF); Hematopoietic stem cells; HIV; Multiple myeloma (MM); Non Hodgkin's lymphoma (NHL); SDF 1 (CXCL12)

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; [[1 (3,5 DICHLOROBENZENESULFONYL)PYRROLIDINECARBONYL]AMINO] 4 [4 METHYL[METHYL[2 [4 (3 O TOLYL UREIDO)PHENYL]ACETYL]AMINO]PENTANOYLAMINO]BUTYRIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIO 5192; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; KRH 1636; KRH 3955; MELPHALAN; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; N [4 GUANIDINO 1 [1 NAPHTHALEN 1 YL ETHYLCARBAMOYL]BUTYL] 4 [[(PYRIDIN 2 YLMETHYL)AMINO]METHYL]BENZAMIDE; N,N DIPROPYL N' [4 [[[(1H IMIDAZOL 2 YL)METHYL][(1 METHYL 1H IMIDAZOL 2 YL)METHYL]AMINO]METHYL]BENZYL] N' METHYLBUTANE 1,4 DIAMINE TRITARTRATE]; NATALIZUMAB; NILOTINIB; PLACEBO; PLERIXAFOR; PLERIXAFOR CU 64; RADIOPHARMACEUTICAL AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; T 140; TN 14003; UNCLASSIFIED DRUG;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CIRCULATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIZATION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; INTRACRANIAL TUMOR; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; STOMACH CANCER; T CELL LEUKEMIA;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; RECEPTORS, CXCR4;

EID: 78049255337     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.08.009     Document Type: Review

References (72)

1. Abraham M., Beider K., Wald H., Weiss I.D., Zipori D., Galun E., Nagler A., Eizenberg O., Peled A. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia 2009, 23:1378-1388.
2. Azab A.K., Runnels J.M., Pitsillides C., Moreau A.S., Azab F., Leleu X., Jia X., Wright R., Ospina B., Carlson A.L., Alt C., Burwick N., Roccaro A.M., Ngo H.T., Farag M., Melhem M.R., Sacco A., Munshi N.C., Hideshima T., Rollins B.J., Anderson K.C., Kung A.L., Lin C.P., Ghobrial I.M. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113:4341-4351.
3. Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies. Future directions. Bone Marrow Transplant 2009, 43:188-195.
4. Bonig H., Chudziak D., Priestley G., Papayannopoulou T. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol 2009, 37:402-415.
5. Bridger G.J., Skerlj R.T., Hernandez-Abad P.E., Bogucki D.E., Wang Z., Zhou Y., Nan S., Boehringer E.M., Wilson T., Crawford J., Metz M., Hatse S., Princen K., De Clercq E., Schols D. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication. J Med Chem 2010, 53:1250-1260.
6. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., Liles W.C., Li X., Graham-Evans B., Campbell T.B., Calandra G., Bridger G., Dale D.C., Srour E.F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
7. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
8. Burger J.A., Stewart D.J. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs 2009, 18:481-490.
9. Burroughs L., Mielcarek M., Little M.T., Bridger G., Macfarland R., Fricker S., Labrecque J., Sandmaier B.M., Storb R. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005, 106:4002-4008.
10. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
11. Cashen A., Lopez S., Gao F., Calandra G., MacFarland R., Badel K., DiPersio J. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:1253-1261.
12. Colmone A., Amorim M., Pontier A.L., Wang S., Jablonski E., Sipkins D.A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008, 322:1861-1865.
13. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003, 2:581-587.
14. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009, 77:1655-1664.
15. Devine S.M., Vij R., Rettig M., Todt L., McGlauchlen K., Fisher N., Devine H., Link D.C., Calandra G., Bridger G., Westervelt P., DiPersio J.F. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998.
16. + cell to Imatinib and Nilotinib. Leuk Lymphoma 2009, 50:1676-1686.
17. DiPersio J.F., Micallef I.N., Stiff P.J., Bolwell B.J., Maziarz R.T., Jacobsen E., Nademanee A., McCarty J., Bridger G., Calandra G. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
18. DiPersio J.F., Stadmauer E.A., Nademanee A., Micallef I.N.M., Stiff P.J., Kaufman J.L., Maziarz R.T., Hosing C., Früehauf S., Horwitz M., Cooper D., Bridger G., Calandra G. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
19. DiPersio J.F., Uy G.L., Yasothan U., Kirkpatrick P. Plerixafor. Nat Rev Drug Discov 2009, 6:105.
20. Donahue R.E., Jin P., Bonifacino A.C., Metzger M.E., Ren J., Wang E., Stroncek D. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009, 114:2530-2541.
21. Dugan M.J., Maziarz R.T., Bensinger W.I., Nademanee A., Liesveld J., Badel K., Dehner C., Gibney C., Bridger G., Calandra G. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010, 45:39-47.
22. Esté J.A., Telenti A. HIV entry inhibitors. Lancet 2007, 370:81-88.
23. Flomenberg N., Devine S.M., DiPersio J.F., Liesveld J.L., McCarty J.M., Rowley S.D., Vesole D.H., Badel K., Calandra G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
24. Fowler C.J., Dunn A., Hayes-Lattin B., Hansen K., Hansen L., Lanier K., Nelson V., Kovacsovics T., Leis J., Calandra G., Maziarz R.T. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009, 43:909.
25. Fricker S.P. A novel CXCR4 antagonist for hematopoietic stem cell mobilization. Expert Opin Investig Drugs 2008, 17:1749-1760.
26. Fricker S.P., Anastassov V., Cox J., Darkes M.C., Grujic O., Idzan S.R., Labrecque J., Lau G., Mosi R.M., Nelson K.L., Qin L., Santucci Z., Wong R.S. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 2006, 72:588-596.
27. Fukuda S., Bian H., King A.G., Pelus L.M. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 2007, 110:860-869.
28. Gerlach L.O., Jakobsen J.S., Jensen K.P., Rosenkilde M.R., Skerlj R.T., Ryde U., Bridger G.J., Schwartz T.W. Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. Biochemistry 2003, 42:710-717.
29. Giralt S., Stadtmauer E.A., Harousseau J.L., Palumbo A., Bensinger W., Comenzo R.L., Kumar S., Munshi N.C., Dispenzieri A., Kyle R., Merlini G., San Miguel J., Ludwig H., Hajek R., Jagannath S., Blade J., Lonial S., Dimopoulos M.A., Einsele H., Barlogie B., Anderson K.C., Gertz M., Attal M., Tosi P., Sonneveld P., Boccadoro M., Morgan G., Sezer O., Mateos M.V., Cavo M., Joshua D., Turesson I., Chen W., Shimizu K., Powles R., Richardson P.G., Niesvizky R., Rajkumar S.V., Durie B.G. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD3100). Leukemia 2009, 23:1904-1912.
30. Greinix H.T., Worel N. New agents for mobilizing peripheral blood stem cells. Transfus Apher Sci 2009, 41:67-71.
31. Hatse S., Princen K., Bridger G., De Clercq E., Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527:255-262.
32. Holtan S.G., Porrata L.F., Micallef I.N., Padley D.J., Inwards D.J., Ansell S.A., Johnston P.B., Gastineau D.A., Markovic S.N. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007, 7:315-318.
33. Ichiyama K., Yokoyama-Kumakura S., Tanaka Y., Tanaka R., Hirose K., Bannai K., Edamatsu T., Yanaka M., Niitani Y., Miyano-Kurosaki N., Takaku H., Koyanagi Y., Yamamoto N. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 2003, 100:4185-4190.
34. 64Cu-AMD3100 - a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem 2009, 17:1486-1493.
35. Kalatskaya I., Berchiche Y.A., Gravel S., Limberg B.J., Rosenbaum J.S., Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009, 75:1240-1247.
36. Kawaguchi A., Orba Y., Kimura T., Iha H., Ogata M., Tsuji T., Ainai A., Sata T., Okamoto T., Hall W.W., Sawa H., Hasegawa H. Inhibition of the SDF-1α-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood 2009, 114:2961-2968.
37. Kazmierski W.M., Gudmundsson K.S., Piscitelli S.C. Small molecule CCR5 and CXCR4-based viral entry inhibitors for anti-HIV therapy currently in development. Annu Rep Med Chem 2007, 42:301-320.
38. Khan A., Nicholson G., Greenman J., Madden L., McRobbie G., Pannecouque C., De Clercq E., Ullom R., Maples D.L., Maples R.D., Silversides J.D., Hubin T.J., Archibald S.J. Binding optimization through coordination chemistry: CXCR4 chemokine receptor antagonists from ultrarigid metal complexes. J Am Chem Soc 2009, 131:3416-3417.
39. Kurtova A.V., Tamayo A.T., Ford R.J., Burger J.A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009, 113:4604-4613.
40. + hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 2005, 77:427-436.
41. Lee H.J., Kim S.W., Kim H.Y., Li S., Yun H.J., Song K.S., Kim S., Jo D.Y. Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer. Int J Oncol 2009, 34:473-480.
42. Lévesque J.P., Hendy J., Takamatsu Y., Simmons P.J., Bendall L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003, 111:187-196.
43. Liles W.C., Broxmeyer H.E., Rodger E., Wood B., Hübel K., Cooper S., Hangoc G., Bridger G.J., Henson G.W., Calandra G., Dale D.C. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
44. Liles W.C., Rodger E., Broxmeyer H.E., Dehner C., Badel K., Calandra G., Christensen J., Wood B., Price T.H., Dale D.C. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45:295-300.
45. Moyle G., DeJesus E., Boffito M., Wong R., Coakley E., Gibney G., Badel K., Calandra G., Bridger G., Becker S. CXCR4 antagonism: proof of activity with AMD11070. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 25-28 February 2007 2007, Abstract # 511.
46. Moyle G., DeJesus E., Boffito M., Wong R.S., Gibney C., Badel K., MacFarland R., Calandra G., Bridger G., Becker S. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis 2009, 48:798-805.
47. Murakami T., Kumakura S., Yamazaki T., Tanaka R., Hamatake M., Okuma K., Huang W., Toma J., Komano J., Yanaka M., Tanaka Y., Yamamoto N. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother 2009, 53:2940-2948.
48. Nervi B., Link D.C., DiPersio J.F. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006, 99:690-705.
49. Nervi B., Ramirez P., Rettig M.P., Uy G.L., Holt M.S., Ritchey J.K., Prior J.L., Piwnica-Worms D., Bridger G., Ley T.J., DiPersio J.F. Characterization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
50. Pelus L.M., Fukuda S. Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. Leukemia 2008, 22:466-473.
51. Pepinsky R.B., Lee W.C., Cornebise M., Gill A., Wortham K., Chen L.L., Leone D.R., Giza K., Dolinski B.M., Perper S., Nickerson-Nutter C., Lepage D., Chakraborty A., Whalley E.T., Petter R.C., Adams S.P., Lobb R.R., Scott D.M. Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties. J Pharmacol Exp Ther 2005, 312:742-750.
52. Perseghin P., Terruzzi E., Dassi M., Baldini V., Parma M., Coluccia P., Accorsi P., Confalonieri G., Tavecchia L., Verga L., Ravagnani F., Iacone A., Pogliani E.M., Pioltelli P. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009, 41:33-37.
53. Pitchford S.C., Furze R.C., Jones C.P., Wengner A.M., Rankin S.M. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 2009, 4:62-72.
54. Pusic I., Jiang S.Y., Landua S., Uy G.L., Rettig M.P., Cashen A.F., Westervelt P., Vij R., Abboud C.N., Stockerl-Goldstein K.E., Sempek D.S., Smith A.L., DiPersio J.F. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
55. Ramirez P., Rettig M.P., Uy G.L., Deych E., Holt M.S., Ritchey J.K., DiPersio J.F. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009, 114:1340-1343.
56. Rettig M.P., Ramirez P., Nervi B., DiPersio J.F. CXCR4 and mobilization of hematopoietic precursors. Methods Enzymol 2009, 460:57-90.
57. Rettig M.P., Shannon W.D., Ritchey J., Holt M., McFarland K., Lopez S., Gabriel J., DiPersio J.F. Characterization of human CD34+ hematopoietic stem cells following administration of G-CSF or plerixafor. Blood 2008, 112:367a.
58. Rubin J.B., Kung A.L., Klein R.S., Chan J.A., Sun Y., Schmidt K., Kieran M.W., Luster A.D., Segal R.A. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003, 100:13513-13518.
59. Saag M., Rosenkranz S., Becker S., Klingman K., Kallungal B., Zadzilka A., Coakley E., Acosta E., Calandra G., Johnson V. Proof of concept of ARV activity of AMD11070 (an orally administered CXCR4 entry inhibitor); results of the first dosing cohort A studied in ACTG Protocol A5210. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 25-28 February 2007 2007, Abstract # 512.
60. Schols D., Claes S., Hatse S., Princen K., Vermeire K., De Clercq E., Skerlj R., Bridger G., Calandra G. Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 10-13 February 2003 2003, Abstract # 563.
61. Shepherd R.M., Capoccia B.J., Devine S.M., Dipersio J., Trinkaus K.M., Ingram D., Link D.C. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood 2006, 108:3662-3667.
62. Stewart D.A., Smith C., MacFarland R., Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with Non-Hodgkin Lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009, 15:39-46.
63. Stiff P., Micallef I., McCarthy P., Magalhaes-Silverman M., Weisdorf D., Territo M., Badel K., Calandra G. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009, 15:249-256.
64. Stone N.D., Dunaway S.B., Flexner C., Tierney C., Calandra G.B., Becker S., Cao Y.J., Wiggins I.P., Conley J., MacFarland R.T., Park J.G., Lalama C., Snyder S., Kallungal B., Klingman K.L., Hendrix C.W. Multiple-dose escalation study of the safety, pharmacokinetics, and biological activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 2007, 51:2351-2358.
65. Tamamura H., Tsutsumi H., Masuno H., Mizokami S., Hiramatsu K., Wang Z., Trent J.O., Nakashima H., Yamamoto N., Peiper S.C., Fujii N. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs. Org Biomol Chem 2006, 4:2354-2357.
66. Traynor K. Plerixafor approved for autologous hematopoietic stem-cell transplantation. Am J Health Syst Pharm 2009, 66:112.
67. Trent J.O., Wang Z.X., Murray J.L., Shao W., Tamamura H., Fujii N., Peiper S.C. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem 2003, 278:47136-47144.
68. Tricot G., Cottler-Fox M.H., Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010, 45:63-68.
69. Uy G.L., Rettig M.P., Cashen A.F. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther 2008, 8:1797-1804.
70. Vose J.M., Ho A.D., Coiffier B., Corradini P., Khouri I., Sureda A., Van Besien K., DiPersio J. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009, 50:1412-1421.
71. Wagstaff A.J. Plerixafor in patients with non-Hodgkin's lymphoma or multiple myeloma. Drugs 2009, 69:319-326.
72. Wong R.S.Y., Bodart V., Metz M., Labrecque J., Bridger G., Fricker S.P. Comparison of the potential multiple binding modes of bicyclam, monocyclam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 2008, 74:1485-1495.